Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity
Authors:
- 1 December 2017
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 268, 92-101
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Health (1R01CA193880-01A1, U54CA210181)
- U.S. Department of War (W81XWH-12-1-0414)
- Ernest Cockrell Jr. Distinguished Endowed Chair fund
- Dottie and Jimmy C. Adair Myelodysplastic Syndrome Treatment and Research Funding
This publication has 48 references indexed in Scilit:
- Cisplatin-crosslinked glutathione-sensitive micelles loaded with doxorubicin for combination and targeted therapy of tumorsCarbohydrate Polymers, 2017
- Novel delivery approaches for cancer therapeuticsJournal of Controlled Release, 2015
- Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancerScientific Reports, 2015
- Engineered nanomedicine for myeloma and bone microenvironment targetingProceedings of the National Academy of Sciences, 2014
- An HPLC–MS/MS method for simultaneous determination of decitabine and its valyl prodrug valdecitabine in rat plasmaJournal of Chromatography B, 2013
- A Novel Nanoparticulate Formulation of Arsenic Trioxide with Enhanced Therapeutic Efficacy in a Murine Model of Breast CancerClinical Cancer Research, 2010
- Decitabine in the treatment of myelodysplastic syndromes2007
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Preclinical Evaluation of Gemcitabine Combination Regimens for Application in Acute Myeloid LeukemiaClinical Cancer Research, 2005
- Chromosomal Instability and Tumors Promoted by DNA HypomethylationScience, 2003